title: Multi-kinase inhibitors, AURKs and cancer.
abstract: Inhibitors that impact function of kinases are valuable both for the biological research as well as therapy of kinase-associated diseases, such as different cancers. There are quite a number of inhibitors, which are quite specific for certain kinases and several of them are either already approved for the cancer therapy or are in clinical studies of various phases. However, that does not mean that each single kinase inhibitor is suitable for targeted therapy. Some of them are not effective others might be toxic or fail some other criteria for the use in vivo. On the other hand, even in case of successful therapy, many responders eventually develop resistance to the inhibitors. The limitations of various single kinase inhibitors can be fought using compounds which target multiple kinases. This tactics can increase effectiveness of the inhibitors by the synergistic effect or help to diminish the likelihood of drug resistance. To date, several families of kinases are quite popular targets of the inhibition in cancers, such as tyrosine kinases, cycle-dependent kinases, mitogen-activated protein kinases, phosphoinositide 3-kinases as well as their pathway "players" and aurora kinases. Aurora kinases play an important role in the control of the mitosis and are often altered in diverse human cancers. Here, we will describe the most interesting multi-kinase inhibitors which inhibit aurora kinases among other targets and their use in preclinical and clinical cancer studies.
authors.affiliation: University of Bern, Vetsuisse Faculty, Institute of Animal Pathology, 3012, Bern, Switzerland. j.cicenas@mapkinases.eu.|MAP Kinase Resource, Melchiorstrasse 9, 3027, Bern, Switzerland. j.cicenas@mapkinases.eu.|Proteomics Centre, Vilnius University Institute of Biochemistry, 08662, Vilnius, Lithuania. j.cicenas@mapkinases.eu.|CALIPHO, Swiss Institute of Bioinformatics, CMU1, ru Michael Servet, 1211, Geneva, Switzerland. j.cicenas@mapkinases.eu.
authors.forename: Jonas
authors.initials: J
authors.lastname: Cicenas
authors.affiliation: Bethlehemacker Secondary School, 3027, Bern, Switzerland.
authors.forename: Erikas
authors.initials: E
authors.lastname: Cicenas
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D064127:Aurora Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D064127:Aurora Kinases
keywords: Aurora kinases; Cancer; Cell cycle; Multi-kinase inhibitors; Protein kinases